All In Biotech

Drug Trial Radar · NCT03098615

Study Evaluating the Effect of Jublia on Dermatophytomas

An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas

Last checked: Nov 20, 2026Latest source record: Dec 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

19

Actual

Start

Sep 2015

Primary completion

May 2017

Study completion Jul 2018

Sponsor

Lead sponsor
University of Alabama at BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 4, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will examine how Jublia affects dermatophytomas, which are difficult to treat with other therapeutic options.

Conditions

  • Onychomycosis
  • Dermatophytosis

Interventions

  • Jublia (Efinaconazole 10% Topical Solution)Drug

    Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Elimination of Dermatophytomas That Occur in Distal Lateral Subungual Onychomycosis (DLSO)Time frame: week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Kirklin Clinic

    Birmingham, Alabama

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.